Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 33.39% | -22.72% | -14.39% | -49.30% | 49.59% |
| Total Depreciation and Amortization | 5.71% | 2.94% | -97.59% | 4,762.07% | 20.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.89% | 35.71% | 82.03% | -68.13% | -6.07% |
| Change in Net Operating Assets | -214.84% | 382.61% | -163.21% | 116.01% | -312.17% |
| Cash from Operations | -0.56% | 4.40% | -40.78% | 33.91% | -47.78% |
| Capital Expenditure | -- | 100.00% | -27.14% | -4.48% | 52.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 151.73% | 51.97% | -256.12% | 1,000.74% | 86.77% |
| Cash from Investing | 150.68% | 52.42% | -259.38% | 910.35% | 85.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -90.63% | -28.00% | -150.51% | 30.26% | 125.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.35% | 14.13% | -129.71% | 49.91% | -24.82% |